Gastroesophageal Junction Adenocarcinoma – VJRegenMed https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Tue, 12 Oct 2021 15:16:37 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png Gastroesophageal Junction Adenocarcinoma – VJRegenMed https://mirror.vjregenmed.com 32 32 Adaptimmune: SPEAR T-cells https://mirror.vjregenmed.com/video/w_-zxokavpg-adaptimmune-spear-t-cells/ Tue, 03 Nov 2020 17:39:49 +0000 http://13.40.107.223/video/w_-zxokavpg-adaptimmune-spear-t-cells/ TCR T-cell therapies (SPEAR T-cells) hold the potential to treat a wide range of cancers. In this video, Helen Tayton-Martin, Chief Business Officer, Adaptimmune, Oxford, UK. discusses the SPEAR T-cells currently under development with Adaptimmune. Dr Taytor-Martin goes on to discuss Adaptimmune’s partnership with GlaxoSmithKline (GSK) and recent advances such as the SURPASS trial (NCT04044859) which investigated ADP-A2M4CD8 in HLA-A2+ subjects with MAGE-A4 positive tumors. This interview took place during the 2020 Meeting on the Mesa congress.

]]>